Successful use of vemurafenib in a patient with resistant hairy cell leukemia

Urnova E.S.; Al'-Radi L.S.; Kuz'mina L.A.; Kariakina A.A.; Kovrigina A.M.; Dvirnyk V.N.; Iakutik I.A.; Sudarikov A.B.; Parovichnikova E.N.; Savchenko V.G.

doi:https://doi.org/

Urnova E.S.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Al'-Radi L.S.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Kuz'mina L.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Kariakina A.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Kovrigina A.M.

Nauchno-klinicheskoe otdelenie gematologicheskoĭ khirurgii Gematologicheskogo nauchnogo tsentra Minzdrava RF, Moskva

Dvirnyk V.N.

National research center for hematology, Ministry of Health of Russia, Moscow, Russia

Iakutik I.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Sudarikov A.B.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Parovichnikova E.N.

Federal state budgetary institution 'Hematological Research Centre', Russian Ministry of Health, Moscow, Russia

Savchenko V.G.

National Research Center for Hematology, Moscow, Russia

Successful use of vemurafenib in a patient with resistant hairy cell leukemia

Authors:

Urnova E.S., Al'-Radi L.S., Kuz'mina L.A., Kariakina A.A., Kovrigina A.M., Dvirnyk V.N., Iakutik I.A., Sudarikov A.B., Parovichnikova E.N., Savchenko V.G.

More about the authors

Journal: Therapeutic Archive. 2013;85(7): 76‑78

Read: 1383 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Urnova ES, Al'-Radi LS, Kuz'mina LA, et al. . Successful use of vemurafenib in a patient with resistant hairy cell leukemia. Therapeutic Archive. 2013;85(7):76‑78. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Abstract:

The paper describes a case of a patient with refractory hairy cell leukemia. In spite of the absence of CD25 expression, the disease was classified as a classical form according to the WHO classification (2008), as also confirmed by the detection of BRAFV600E mutation. The disease was characterized by resistance to all lines of therapy (interferon-α, splenectomy, cladribin). Clinical and hematological remission was achieved within 2 months of administration of the BRAF kinase inhibitor vemurafenib.

Keywords:

hairy cell leukemia

resistant form

vemurafenib

Authors:

Urnova E.S.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Al'-Radi L.S.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Kuz'mina L.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Kariakina A.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Kovrigina A.M.

Nauchno-klinicheskoe otdelenie gematologicheskoĭ khirurgii Gematologicheskogo nauchnogo tsentra Minzdrava RF, Moskva

Dvirnyk V.N.

National research center for hematology, Ministry of Health of Russia, Moscow, Russia

Iakutik I.A.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Sudarikov A.B.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva

Parovichnikova E.N.

Federal state budgetary institution 'Hematological Research Centre', Russian Ministry of Health, Moscow, Russia

Savchenko V.G.

National Research Center for Hematology, Moscow, Russia

Close metadata

References:

Al'-Radi L.S., Pivnik A.V. Osobennosti techeniya i sovremennaya taktika terapii volosatokletochnogo leikoza. Klin onkogematol 2009; 2: 111-120.
Al'-Radi L.S., Pivnik A.V., Zingerman B.V., Kravchenko S.K. Lechenie retsidivov volosatokletochnogo leikoza. Ter arkh 2012; 7: 4-9.
Volkova M.A. Volosatokletochnyi leikoz. V kn: Klinicheskaya onkogematologiya. Rukovodstvo dlya vrachei, 2-e izd. Pod red. M.A. Volkova M: Meditsina 2007: 396-410.
Catovsky D., O'Brien M., Melo J.V. et al. Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia. Semin Oncol 1984; 11: 362-369.
Matutes E., Morilla R., Owusu-Ankomah K. et al. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leukemia & Lymphoma 1994; 14 suppl 1: 57-61.
Bouroncle B., Wiseman B., Doan C. Leukemic reticuloendotheliosis. Blood 1958; 13: 609-630.
Matutes E., Wotherspoon A., Catovsky D. The variant form of hairy-cell leukaemia. In Best Pract & Res Clin Haematol 2003; 16 (1): 41-56.
Tiacci E., Trifonov V., Schiavoni G. et al. BRAF Mutations in Hairy-Cell Leukemia. N Engl J Med 2011; 364: 2305-2315.
Dicker F., Eder C., Jeromin S. et al. BRAFV600E negative hairy cell leukemia is rare and not associated with specific IGHV rearrangements or a specific IGHV mutation status. Haematologica 2012; 97: e-Supplement 1: 377.
Thompson J. Past and present role of interferon in hairy cell leukemia. In: Advances in Blood Disorders series. M.S. Tallman, A. Pulliack (eds.) V. 5. Harwood academic Publishers 2000: 127-139.
Rai K., Davey F., Peterson B. et al. Recobinant α-2b interferon in therapy of previously untreated hairy cell leukemia long-term follow-up results of study by Cancerand Leukemia Group B. Leukemia 1995; 9: 116-120.
Shahid A., Kanti R. Interferon in the treatment of hairy-cell leukemia. In Best Pract & Res Clin Haematol 2003; 16 (1): 69-81.
Else M., Dearden C., Matutes E. et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145: 733-740.
Saven A., Burian C., Koziol J.A., Piro L.D. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-1926.
Dearden C.E., Matutes E., Hilditch B.L. et al. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or claridribine. Br J Haematol 1999; 106: 515-519.
Dietrich S., Glimm H., Andrulis M. et al. BRAF Inhibition in Refractory Hairy-Cell Leukemia N Engl J Med 2012; 366: 21.
Peyrade F., Re D., Ginet C. et al. Low-dose vemurafenb indused complete remission incase of hairy-cell leukemia with a V600E mutation. Haemotologica 2013; 98 (2): e20-e22.
Follows G.A., Smis H., Bloxham D.M. et. al. Rapid response of bialetic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 2013; 161 (1): 150-153.